9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
Trial Timeline
Feb 23, 2021 → Jul 1, 2026
NCT ID
NCT04255849About 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) is a phase 3 stage product being developed by Merck for HPV Positive Oropharyngeal Squamous Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04255849. Target conditions include HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04255849 | Phase 3 | Active |
Competing Products
20 competing products in HPV Positive Oropharyngeal Squamous Cell Carcinoma